Skip to main content
Clinical Trials/NCT07366762
NCT07366762
Completed
Phase 3

Comparison Between the Effect of Periurethral Injection of Platelet-rich Plasma VS Platelet Rich Fibrin in Treatment of Female Stress Urinary Incontinence

Kafrelsheikh University1 site in 1 country40 target enrollmentStarted: July 10, 2024Last updated:

Overview

Phase
Phase 3
Status
Completed
Enrollment
40
Locations
1
Primary Endpoint
changes in the severity of SUI measured by Incontinence Impact Questionnaire (IIQ7)

Overview

Brief Summary

compare the therapeutic effect of periurethral injection of autologous platelet-rich plasma (PRP) and injectable platelet rich fibrin (i-PRF) in treatment of female stress urinary incontinence and comparing the need for re-injection in the two groups.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
30 Years to 75 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Female patients with primary symptoms of SUI confirmed by patient's medical history and clinical examination, including a focused incontinence evaluation
  • Age range of 30-75 years
  • Females unfit for surgery
  • Females with SUI recurrence after previous surgical procedure by suburethal sling
  • Females refusing surgical interventions

Exclusion Criteria

  • Residual urine volume exceeding 100 cc after excretion
  • Evidence of detrusor over-activity on the urodynamic test
  • Active urinary tract or vaginal infection
  • Malignancies of the genitourinary system
  • Patients with genitourinary fistula or urethral diverticulum

Arms & Interventions

group one who had received PRP injections

Active Comparator

Intervention: Platelet Rich Plasma (Biological)

group two who had received i-PRF injections

Active Comparator

Intervention: Platelet rich fibrin (Biological)

Outcomes

Primary Outcomes

changes in the severity of SUI measured by Incontinence Impact Questionnaire (IIQ7)

Time Frame: baseline and three and six months follow up

Secondary Outcomes

  • changes in the severity of SUI using 10 point visual analogue scale(baseline and three and six months follow up)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Marwa Reda Mohamed Gebril

obstetrics and gynecology resident

Kafrelsheikh University

Study Sites (1)

Loading locations...

Similar Trials